• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Ixekizumab, with or without concomitant methotrexate, improves the signs and symptoms of psa for up to 52 weeks of treatment

    Author(s)
    Combe, Bernard
    Tsai, Tsen-Fang
    Odhav, Satish
    Huffstutter, J Eugene
    Sprabery, Aubrey Trevelin
    Lin, Chen-Yen
    Park, So Young
    Hufford, Matthew
    Nash, Peter
    Griffith University Author(s)
    Nash, Peter
    Year published
    2019
    Metadata
    Show full item record
    Abstract
    Background Ixekizumab (IXE) is a high affinity monoclonal antibody selectively targeting interleukin (IL)-17A. It was previously demonstrated that IXE, with or without concomitant methotrexate (MTX), was superior to placebo (PBO) in improving the signs and symptoms of patients with psoriatic arthritis (PsA) for up to 24 weeks1 ,2. Objectives To evaluate the efficacy of IXE, with or without continuous concomitant MTX, for up to 52 weeks of treatment in patients with active PsA. Methods Patients with active PsA who were biologic naïve (SPIRIT-P1, NCT01695239) or had prior inadequate response or intolerance to tumour ...
    View more >
    Background Ixekizumab (IXE) is a high affinity monoclonal antibody selectively targeting interleukin (IL)-17A. It was previously demonstrated that IXE, with or without concomitant methotrexate (MTX), was superior to placebo (PBO) in improving the signs and symptoms of patients with psoriatic arthritis (PsA) for up to 24 weeks1 ,2. Objectives To evaluate the efficacy of IXE, with or without continuous concomitant MTX, for up to 52 weeks of treatment in patients with active PsA. Methods Patients with active PsA who were biologic naïve (SPIRIT-P1, NCT01695239) or had prior inadequate response or intolerance to tumour necrosis factor inhibitors (SPIRIT-P2; NCT02349295) were randomised to PBO (N=224), 80 mg IXE every 4 weeks (IXEQ4W, N=229) or every 2 weeks (IXEQ2W, N=226), after a 160 mg starting dose. In this post-hoc analysis, efficacy was assessed up to Week 52 for the following two subgroups: (i) patients who were treated with IXE as monotherapy i.e. no concomitant conventional disease-modifying anti-rheumatic drugs and (ii) patients who received constant dose of MTX from Weeks 0 to 52. Patients who had MTX dose change were excluded. Efficacy outcome measurements included American College of Rheumatology (ACR) 20/50/70 responses, minimal disease activity (MDA), and disease activity in psoriatic arthritis (DAPSA) low disease activity (LDA) (score ≤ 14). Patients who discontinued from treatment before Week 52 were included in the analysis. Missing values were imputed using non-responder imputation. All analyses were done post-hoc. Results Among patients randomised to IXE at Week 0, 177 (38.9%) patients were treated with IXE monotherapy while 183 (40.2%) patients received constant dose of MTX up to Week 52. The average MTX dose was 15.7 mg/week and 16.0 mg/week for IXEQ4W and IXEQ2W, respectively. Week 52 results are presented in Table 1. At Week 52, similar results were observed between the two groups of patients for the different disease activity measures (ACR, MDA, and DAPSA LDA) and there was also a trend for a numerical higher proportion of patients achieving ACR responses with IXE monotherapy compared to patients with concomitant MTX use. Over time (Weeks 0-52), ACR 20, 50, and 70 response rates increased from baseline and were largely similar between the two subgroups (data not shown). Conclusion In this post-hoc analysis, IXE treatment showed sustained efficacy in patients with PsA up to one year of treatment, with or without concomitant MTX therapy.
    View less >
    Conference Title
    Annals of the Rheumatic Diseases
    Volume
    78
    Issue
    Suppl 2
    DOI
    https://doi.org/10.1136/annrheumdis-2019-eular.1240
    Subject
    Clinical Sciences
    Immunology
    Public Health and Health Services
    Science & Technology
    Life Sciences & Biomedicine
    Rheumatology
    Publication URI
    http://hdl.handle.net/10072/400997
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander